It’s a major series of funding rounds so far for Heidi, here are the details;
Heidi, the AI Care Partner for clinicians globally, today announced the close of a US$100 million Series C funding round led by Blackbird, with participation from other existing investors including Phoenix Court (the home of LocalGlobe, Latitude and Solar funds), Point72 Private Investments, and Headline. The round values Heidi at US$900 million. Alongside the equity round, Heidi has also secured a US$240 million growth investment led by General Catalyst’s Customer Value Fund (CVF), providing large scale go-to-market investment capacity to support Heidi’s rapid growth and scale, bringing the total new funding to US$340M.
The investment supports Heidi’s next phase of growth, which will see a deepening of adoption across the NHS, private healthcare settings and health systems globally, while expanding how Heidi supports clinicians throughout their workflows. This includes helping with the administrative work that surrounds a patient visit, resulting in faster completion of follow-up tasks alongside improved clinical note-taking. The roadmap also includes building the regulatory and clinical safety foundations required to support these capabilities.
“From the day I started Heidi, the ambition was always bigger than writing doctor’s notes. I imagined AI sitting alongside clinicians throughout their work, from documenting consultations to helping carry out the work that follows them,“ said Dr Thomas Kelly, Co-founder and CEO of Heidi. “That’s the ambition we’re continuing to build towards. This round gives us the opportunity to go further in the UK; developing products that work the way the NHS needs them to, investing in the essential regulatory groundwork, and ultimately giving clinicians more time to focus on delivering care.”
Built for healthcare’s defining problem
The Government’s 10 Year Health Plan for England sets a goal of making AI every clinician’s trusted assistant. This ambition sits against a backdrop of a clinical workforce already stretched thin, with a rising admin burden for 80% of NHS professionals, significantly impacting their mental load. Heidi directly alleviates this pressure, aiming to double the world’s healthcare capacity while protecting what matters most: the human connection between clinicians and patients. Heidi is building an AI Care Partner that supports clinicians across the whole working day, from administration and clinical knowledge to the work around the patient visit. Every hour of admin lifted from a clinician’s day is time that can be given back to caring for patients – more time listening, explaining, and treating.
Two years since launch, that demand is evident in the numbers. Heidi’s AI Care Partner has supported more than 175 million patient visits (up from 73 million at Series B), and over 67 million clinical hours, more than tripling since September 2025. The platform is being used in 190 countries and 110 languages. Annual recurring revenue grew from US$1 million to US$50 million (April 2026) in just two years.
“We are proud to continue backing Heidi and their mission to double the world’s healthcare capacity and deliver relief to every clinician across the globe. The team’s strong domain expertise and product – that clinicians deeply trust – make this ambition absolutely achievable. These goals clearly respond to the core challenges in the UK’s health system – clinician wellbeing, retention and patient care – as evidenced by Heidi’s impressive NHS market penetration to date,” said Julia Svennerstål-Hawkins, General Partner at Phoenix Court (the home of LocalGlobe, Latitude and Solar funds).
Trusted by the NHS and global healthcare systems
Since its Series B, Heidi has been adopted across a range of care settings in the UK. Earlier this year, Heidi was selected as sole supplier for the NHS England Midlands, the largest clinical AI documentation procurement in NHS history. The procurement covers 15 acute and community trusts, all Midlands integrated care boards (ICBs) and 1,239 GP practices. In Australia, deployments include The Royal Children’s Hospital Melbourne, Children’s Health Queensland Hospital and Health Service, and Metro South Health. In New Zealand, Heidi was deployed across every emergency department in the country.
From documentation to the full clinical workday
Heidi has moved well beyond the scribe. It is now a connected platform that health organisations trust with the whole clinical day, with deeper connections into the NHS’ electronic health record (EHR) systems. Heidi Evidence, which brings clinical guidance at the point of care, has answered over 10 million queries since launching in March 2026. Heidi also shipped its first hardware device, Remote, a wearable microphone built to work across settings, from surgery to community, alongside Dictate, a voice-to-text feature to allow health systems and workflows to be accessed and written to no matter the location.
Clinical work itself is changing. AI is already supporting clinicians in delivering high-quality care, and increasingly can work through complex healthcare workflows, meaning the manual administration that has clogged health systems for decades is starting to move off clinicians’ desks. What comes back is capacity, and more time for the care only a person can give.
Purpose-built clinical AI
Heidi invested early in purpose-built clinical AI rather than relying on frontier models. Transcription and note generation, which account for the vast majority of Heidi’s compute, run almost entirely on its own models. That lets Heidi pick the right model for each clinical task rather than defaulting to the largest, optimise accuracy, latency and cost together, and reinvest in the product.
These products are designed for safety and quality before they ever reach a clinician. Heidi’s clinical research team leads that work through ongoing testing, validation and published research, and works with regulators as clinical AI regulation takes shape. Alongside technology development, Heidi is already investing in regulatory pathways for advanced clinical functionality in the UK and Europe, and part of this Series C funding will accelerate that programme. As these capabilities advance, clinicians will remain in control of clinical decisions, with their judgement paramount.
Be the first to comment